Nouscom

📍 BS, Switzerland👥 67 employees💰 Last funded Sep 2024
Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
Founded
Investor geography3 countries
United Kingdom
1
Netherlands
1
Italy
1
Investor activity2023–2024 · investors recorded per year
2023120242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nouscom?
Nouscom has 3 investors on record on gritt.io.
When did Nouscom last raise funding?
The most recent investment in Nouscom recorded on gritt.io was in September 2024.
What industry is Nouscom in?
Nouscom operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nouscom based?
Nouscom is headquartered in BS, Switzerland.